Anticoagulation Management

Introduction to Anticoagulants

Apixaban (Eliquis) is a direct Factor Xa inhibitor with a half-life of approximately 12 hours, 27% renal excretion, and 73% biliary and intestinal excretion, and is a P-glycoprotein substrate with CYP3A4 metabolism, as recommended by the American College of Cardiology 1
The combination of Lovenox (enoxaparin) and Eliquis (apixaban) is not recommended due to increased bleeding risk without providing additional thrombotic protection, according to the American College of Cardiology 1

For patients on Eliquis requiring surgery/procedures, the American College of Cardiology recommends discontinuation protocols (3 days before procedure for normal renal function) without bridging with enoxaparin, except in very high thrombotic risk situations, as stated by the French Working Group on Perioperative Hemostasis (GIHP) 2
The GIHP explicitly states that there is no need for heparin bridging when interrupting direct oral anticoagulants like apixaban, except in very high thrombotic risk situations 2

When transitioning between anticoagulants, complete discontinuation of one agent before starting the other is recommended, with specific guidelines for switching between apixaban and enoxaparin, as follows:

The 2024 ACC/AHA guidelines for atrial fibrillation management do not recommend concurrent use of multiple anticoagulants, as combining anticoagulants with different mechanisms of action significantly increases bleeding risk without providing additional thrombotic protection 1
Bridging with enoxaparin when a patient on apixaban needs surgery is not supported by guidelines, increases bleeding risk, and provides no additional thrombotic protection, as stated by multiple guidelines 2, 3

In very specific clinical scenarios involving patients at extremely high thrombotic risk (e.g., recent stent placement with proximal LAD involvement), bridging therapy might be considered, but this should involve IV glycoprotein inhibitors (tirofiban or eptifibatide) rather than enoxaparin 3
Bevacizumab, an anti-VEGF monoclonal antibody, can increase bleeding risk due to its effects on vascular integrity, and concurrent use with enoxaparin further compounds bleeding risk, with recommendations for minimum intervals between administrations, as follows:
Patient Bleeding Risk Recommended Interval
Low 24 hours
Moderate 48 hours
High 72+ hours
The NCCN recommends at least 6 weeks between the last dose of bevacizumab and elective surgery, which corresponds to approximately 2 half-lives of bevacizumab 4
Enoxaparin dosing should be adjusted for patients with renal impairment (CrCl <30 mL/min), and lower doses should be considered for elderly patients (≥75 years), as recommended by reputable medical societies, such as the American Heart Association and the American College of Cardiology 5
Baseline coagulation studies should be performed before initiating either agent, and regular monitoring of hemoglobin/hematocrit and vigilance for signs of bleeding are necessary, with immediate medical attention for any signs of significant bleeding, as recommended by guidelines 4